Enovis Reports 5% Organic Q3 Sales Growth, Raises 2026 Earnings Outlook

What happened

Enovis reported third-quarter 2026 net sales of $558.7 million, up 2% from a year earlier as reported and 5% organically. It posted $3.4 million in net income and adjusted diluted earnings per share of $0.88, and raised its 2026 adjusted EBITDA and adjusted earnings outlook.

Confirmed

Global impact / market context

Organic sales growth and higher gross profit per sale could support Enovis’ earnings, while stronger guidance signals management expects improved full-year results. The planned robotics acquisition could add technology to its surgical offering, but the article gives no purchase price or expected financial contribution.

Analyst inference

Reported sales grew more slowly than organic sales, indicating that the company’s reported growth measure and its underlying business growth differ. Reconstructive sales rose 6%, while Prevention & Recovery fell 2% as reported, showing that performance varied across Enovis’ businesses.

Analyst inference

What to watch

1. Watch whether subsequent reports show sales growth continuing and whether the raised 2026 outlook is achieved: revenue guidance is $2.32 billion to $2.35 billion. Analyst inference
2. Track progress on the planned eCential Robotics acquisition, including any disclosed completion timing and financial terms; the article does not provide those details. Analyst inference
3. Look for further results by business: Reconstructive sales grew 6% and Prevention & Recovery sales declined 2% as reported in the third quarter. Analyst inference

Evidence

• Original source link unavailable